Thiotepa is supplied in single-dose vials in 15 mg and 100 mg strength to administer intravenously, intracavitary, or intravesically. This medicine dosage should be given only as per the healthcare professional’s prescription. 

The most common side-effects of Thiotepa are vomiting, abdominal pain, nausea, anorexia, fatigue, rash, weakness, urticaria, laryngeal edema, anaphylactic shock, asthma, wheezing, contact dermatitis, pain at the injection site, vision dizziness, blurred vision, headache, dysuria, urinary retention, chemical cystitis, amenorrhea, conjunctivitis and interference with the spermatogenesis.

• One should not administer live or attenuated viral or bacterial vaccines to a patient treated with this medication until the immunosuppressive effects have resolved.
• Treatment with Thiotepa can be responsible for skin discolouration, blistering, desquamation, pruritus and peeling that could be severe in the groin, skin folds, and axillae in the neck area, and under dressings.
• One should instruct patients to shower or bathe with the water at least a couple of times daily through 48 hours after the administration of Thiotepa.
• One must monitor patients for serum transaminases and bilirubin daily through BMT Day +28 and provide supportive care to patients who develop the hepatic veno-occlusive disease.
• Febrile reactions and discharge from a subcutaneous lesion can occur as the result of the breakdown of the tumor tissue.
• One should inform the patients about developing low blood cell counts required for a hematopoietic progenitor cell infusion.
• In some patients, prolonged apnea occurred when succinylcholine was administered before surgery, following combined use of the Thiotepa 15 mg and other anticancer drugs.
• One must instruct patients to report to their doctor in case of bleeding or fever.
• Counsel patients on the symptoms of hypersensitivity and seek emergency help if they experience any of these symptoms.
• Advise males with female sexual partners about the reproductive potential to use effective contraception during the treatment with this drug and for at least 12 months after the final dose of the Thiotepa.
• Healthcare professionals should instruct patients that this medicine may produce infertility. Male patients must be informed about the possibility of sperm conservation before initiating the therapy.
• One should advise patients to avoid breastfeeding while receiving this medication.

What class of drug is Thiotepa?

The drug Thiotepa belongs to the alkylating agent category. The radiomimetic action of Thiotepa is believed to occur through the release of ethyleneimine radicals which, like irradiation, disrupt the bonds of DNA. 

How is Thiotepa administered?

The medicine Thiotepa is administered intravenously, intracavitary, or intravesically.  

Is Thiotepa cytotoxic?

The drug, Thiotepa is a cytotoxic agent of the polyfunctional type, related chemically and pharmacologically to the nitrogen mustard. 

How to store the drug Thiotepa?

One should store the drug Thiotepa at 2°C to 8°C (36° to 46°F). Do not freeze the medicine. 

Is Thiotepa available in India?

The medicine Thiotepa is a (prescription drug, doctor-prescribed medication, or health care professional-prescribed medicine) pharmaceutical drug that can be legally dispensed against a medical prescription.

Thiotepa vials can be made available through the network of authorized distributors in India. (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)

Can you send the drug Thiotepa to a foreign destination?

Buy generic Thiotepa medicine online from a leading supplier at the best/lowest price in India. Indian Generic Medicines can assist in the delivery of this medicine; the doctor prescribed medication to the USA, UK, Canada, Australia, China, Saudi Arabia, Thailand, South Africa, Zambia, Pakistan, Qatar, Kuwait, Sweden, Hong kong, UAE, Philippines, Kazakhstan, Turkey, Singapore, Malaysia, Sri Lanka, Uzbekistan Afghanistan, Nepal, Japan, and many more countries.

Meta description: Thiotepa is used in treatment of patients who have Adenocarcinoma of the Breast or Ovary, Malignant Effusions, Superficial Papillary Carcinoma of the Urinary Bladder, Class 3 Beta-Thalassemia.